1. Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients.
- Author
-
Kwon HS, Hwang M, Koh SH, Choi SH, Lee JH, Kim HJ, Park SH, Park HH, Jeong JH, Han MH, and Kim JY
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Prognosis, Republic of Korea, Biomarkers blood, Phosphorylation, Amyloid beta-Peptides blood, Amyloid beta-Peptides metabolism, Amyloid blood, Amyloid metabolism, Cohort Studies, tau Proteins blood, Positron-Emission Tomography methods, Cognitive Dysfunction blood
- Abstract
We investigated plasma phosphorylated tau217 (p-tau217) and p-tau181 efficacy in predicting positive amyloid positron emission tomography (PET) results and cognitive stage transitions. Plasma p-tau217 and p-tau181 were measured in participants who were cognitively unimpaired (CU, n = 121), had mild cognitive impairment (n = 102), or dementia (n = 75) from two independent cohorts (Cohort 1: KBASE-V and Cohort 2: Asan) who underwent amyloid PET. In Cohort 1, plasma p-tau217 (area under the curve [AUC] = 0.938, P < 0.001) outperformed p-tau181 (AUC = 0.857, P < 0.001) in predicting amyloid PET positivity (P
difference < 0.001). In Cohort 2, p-tau217 (AUC = 0.893, P < 0.001) and p-tau181 (AUC = 0.856, P < 0.001) showed comparably good discrimination for predicting amyloid PET positivity (P = 0.377). P-tau217 (AUC = 0.852, P < 0.001) and p-tau181 (AUC = 0.828, P < 0.001) demonstrated similarly good discriminations for predicting cognitive stage transition (Pdifference = 0.093). Plasma p-tau217 and p-tau181 predicted amyloid PET positivity and cognitive stage transitions well. Plasma p-tau217 might perform better, especially in the early stages., Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Consent for publication: Not applicable. Consent statement: This study was performed in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki and was approved by the Institutional Review Boards of the Asan Medical Center (Approval #2018-0614), Inha University Hospital (INHAUH 2015-03-021), and each participating center. All participants or their proxies provided written informed consent., (© 2025. The Author(s).)- Published
- 2025
- Full Text
- View/download PDF